WA
VRTX icon

Wealth Alliance’s Vertex Pharmaceuticals VRTX Stock Holding History

Wealth Alliance’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$690K Sell
1,546
-19
-1% -$8.86K 0.07% 240
2025
Q4 		$710K Buy
1,565
+306
+24% +$132K 0.07% 240
2025
Q3 		$493K Buy
+1,259
New +$526K 0.05% 306
2024
Q1 		– Sell
-526
Closed -$214K – 539
2023
Q4 		$214K Buy
+526
New +$194K 0.03% 469

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Wealth Alliance's VRTX Position: Q1 2026 in Review

Wealth Alliance reduced its Vertex Pharmaceuticals (VRTX) stake by 1.2% in Q1 2026, selling an estimated $8.86K and leaving 1,546 shares worth $690K. The position accounts for 0.07% of the portfolio, ranked #240.

Wealth Alliance first reported a position in VRTX in Q4 2023 and has held it in 4 quarters since. The position peaked at $710K in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Wealth Alliance held 1,546 shares of Vertex Pharmaceuticals worth $690K as of Q1 2026.
  • Wealth Alliance sold 19 Vertex Pharmaceuticals shares in Q1 2026, an estimated $8.86K.
  • Vertex Pharmaceuticals made up 0.07% of Wealth Alliance's portfolio in Q1 2026, its #240 holding.
  • Wealth Alliance first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 4 quarters since.
  • Wealth Alliance's Vertex Pharmaceuticals position peaked at $710K in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Wealth Alliance's 13F filing for Q1 2026, filed 14 May 2026.